These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 1761121)

  • 1. Prophylactic heparin does not prevent liver veno-occlusive disease following autologous bone marrow transplantation.
    Marsa-Vila L; Gorin NC; Laporte JP; Labopin M; Dupuy-Montbrun MC; Fouillard L; Isnard F; Najman A
    Eur J Haematol; 1991 Nov; 47(5):346-54. PubMed ID: 1761121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of heparin prophylaxis for veno-occlusive disease of the liver in children undergoing bone marrow transplantation.
    Rosenthal J; Sender L; Secola R; Killen R; Millerick M; Murphy L; Cairo MS
    Bone Marrow Transplant; 1996 Jul; 18(1):185-91. PubMed ID: 8832013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial.
    Attal M; Huguet F; Rubie H; Huynh A; Charlet JP; Payen JL; Voigt JJ; Brousset P; Selves J; Muller C
    Blood; 1992 Jun; 79(11):2834-40. PubMed ID: 1586733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: possible beneficial use of low molecular weight heparin.
    Simon M; Hahn T; Ford LA; Anderson B; Swinnich D; Baer MR; Bambach B; Bernstein SH; Bernstein ZP; Czuczman MS; Slack JL; Wetzler M; Herzig G; Schriber J; McCarthy PL
    Bone Marrow Transplant; 2001 Mar; 27(6):627-33. PubMed ID: 11319593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients.
    Or R; Nagler A; Shpilberg O; Elad S; Naparstek E; Kapelushnik J; Cass Y; Gillis S; Chetrit A; Slavin S; Eldor A
    Transplantation; 1996 Apr; 61(7):1067-71. PubMed ID: 8623187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Veno-occlusive disease prophylaxis with fresh frozen plasma and heparin in bone marrow transplantation.
    Batsis I; Yannaki E; Kaloyannidis P; Sakellari I; Smias C; Georgoulis I; Fassas A; Anagnostopoulos A
    Thromb Res; 2006; 118(5):611-8. PubMed ID: 16330084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot study of continuous infusion heparin for the prevention of hepatic veno-occlusive disease after bone marrow transplantation.
    Bearman SI; Hinds MS; Wolford JL; Petersen FB; Nugent DL; Slichter SJ; Shulman HM; McDonald GB
    Bone Marrow Transplant; 1990 Jun; 5(6):407-11. PubMed ID: 2369681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylactic low-dose heparin or prostaglandin E1 may prevent severe veno-occlusive disease of the liver after allogeneic hematopoietic stem cell transplantation in Korean children.
    Song JS; Seo JJ; Moon HN; Ghim T; Im HJ
    J Korean Med Sci; 2006 Oct; 21(5):897-903. PubMed ID: 17043426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients.
    McDonald GB; Hinds MS; Fisher LD; Schoch HG; Wolford JL; Banaji M; Hardin BJ; Shulman HM; Clift RA
    Ann Intern Med; 1993 Feb; 118(4):255-67. PubMed ID: 8420443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of prostaglandin E1 for prevention of liver veno-occlusive disease in leukaemic patients treated by allogeneic bone marrow transplantation.
    Gluckman E; Jolivet I; Scrobohaci ML; Devergie A; Traineau R; Bourdeau-Esperou H; Lehn P; Faure P; Drouet L
    Br J Haematol; 1990 Mar; 74(3):277-81. PubMed ID: 2159315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous immunoglobulin and the risk of hepatic veno-occlusive disease after bone marrow transplantation.
    Sullivan KM; Kansu E; Storer B; Jocom J; Emerson G; Reagan T; Emerson V; Siadak MF; Davis C; Appelbaum FR; Buckner CD; Hansen JA; Shulman HM; Storb R; McDonald GB
    Biol Blood Marrow Transplant; 1998; 4(1):20-6. PubMed ID: 9701388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party.
    Carreras E; Bertz H; Arcese W; Vernant JP; Tomás JF; Hagglund H; Bandini G; Esperou H; Russell J; de la Rubia J; Di Girolamo G; Demuynck H; Hartmann O; Clausen J; Ruutu T; Leblond V; Iriondo A; Bosi A; Ben-Bassat I; Koza V; Gratwohl A; Apperley JF
    Blood; 1998 Nov; 92(10):3599-604. PubMed ID: 9808553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Low dose heparin for the prevention of hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation].
    Chen J; Zhu KE; Zhang T; Zhong J; Chen ST; Zeng HL
    Zhonghua Nei Ke Za Zhi; 2007 Feb; 46(2):140-2. PubMed ID: 17445443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of PGE1 to prevent veno-occlusive disease of the liver after bone marrow transplantation.
    Gluckman E; Jolivet I; Scrobohaci ML; Devergie A; Traineau R; Bourdeau-Espérou H; Lehn P; Faure P; Drouet L
    Nouv Rev Fr Hematol (1978); 1990; 32(1):1-3. PubMed ID: 2349075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Veno-occlusive disease (VOD) of the liver in Korean patients following allogeneic bone marrow transplantation (BMT): efficacy of recombinant human tissue plasminogen activator (rt-PA) treatment.
    Lee JH; Lee KH; Choi JS; Zang DY; Kim SB; Kim SW; Suh C; Lee JS; Kim WK; Lee YS; Kim SH
    J Korean Med Sci; 1996 Apr; 11(2):118-26. PubMed ID: 8835758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized trial of heparin plus ursodiol vs. heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation.
    Park SH; Lee MH; Lee H; Kim HS; Kim K; Kim WS; Jung CW; Im YH; Yoon SS; Kang WK; Park K; Park CH; Kim SW
    Bone Marrow Transplant; 2002 Jan; 29(2):137-43. PubMed ID: 11850708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A trial use of prostaglandin E1 for prevention of hepatic veno-occlusive disease after allogeneic bone marrow transplantation].
    Morio S; Oh H; Kogure K; Ishii H; Ishii A; Nakaseko C; Ikegami T; Kawano E; Matsuura Y; Nishimura M
    Rinsho Ketsueki; 1994 Sep; 35(9):846-52. PubMed ID: 7967053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation.
    Hägglund H; Remberger M; Klaesson S; Lönnqvist B; Ljungman P; Ringdén O
    Blood; 1998 Dec; 92(12):4568-72. PubMed ID: 9845522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency of veno-occlusive disease of the liver in bone marrow transplantation with a modified busulfan/cyclophosphamide preparative regimen.
    Brodsky R; Topolsky D; Crilley P; Bulova S; Brodsky I
    Am J Clin Oncol; 1990 Jun; 13(3):221-5. PubMed ID: 2346127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defibrotide in the prevention and treatment of veno-occlusive disease in autologous and allogeneic stem cell transplantation in children.
    Qureshi A; Marshall L; Lancaster D
    Pediatr Blood Cancer; 2008 Apr; 50(4):831-2. PubMed ID: 18286502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.